menu search

Usd/chf weekly outlook

USD/CHF’s pull back from 0.8874 was deeper than expected, but it recovered quickly after hitting 0.8743. Initial bias stays neutral this week first....

September 2, 2023, 1:26 pm

Usd/cad weekly outlook

USD/CAD’s pull back from 1.3638 was deeper than expected, but it recovered strongly have hitting 1.3488. Initial bias is turned neutral this week fi...

September 2, 2023, 1:16 pm

Gbp/jpy weekly outlook

GBP/JPY stayed in range of 183.35/186.75 last week and outlook is unchanged. Initial bias remains neutral this week first. On the downside, break of 1...

September 2, 2023, 1:02 pm

Eur/chf weekly outlook

EUR/CHF recovered to 0.9601 last week but reversed from there. Initial bias stays neutral this week and larger down trend is still in favor to continu...

September 2, 2023, 12:43 pm

International seaways: it's time to jump onboard - strong buy

International Seaways stock has increased by 46% in the last year and has a strong financial position. Q2 2023 saw a significant increase in revenues,...

September 2, 2023, 2:54 am

Bank of canada to pause rate hikes ahead of key jobs data

We expect the Bank of Canada to move back to the sidelines Wednesday, foregoing another interest rate hike. But it’ll keep its options open in case ...

September 2, 2023, 2:01 am

Chip designer arm targeting ipo valuation of up to $55 billion: report

Chip designer ARM targeting IPO valuation of up to $55 billion: report Read Full Story The post Chip de...

September 1, 2023, 10:12 pm

: chip designer arm targets ipo valuation of up to $55 billion: report

Arm’s debut is expected to be one of several that could jump-start a sleepy IPO market. Read Full Story The post : Chip designer ARM ...

September 1, 2023, 10:07 pm

Goldman sachs: the rationale for staying short eur/cad targeting 1.42

Goldman Sachs maintains its recommendation for a short position in EUR/CAD with a target of 1.42 and a ...

September 1, 2023, 7:10 pm

Atai life sciences: rl-007, targeting schizophrenia subpopulation with no fda approved therapies

Atai Life Sciences is advancing RL-007 for the treatment of cognitive impairment associated with schizophrenia, with top-line results expected in the ...

September 1, 2023, 7:02 pm

Chip designer arm targets ipo valuation of up to $55 billion: report

Arm Holdings Ltd.'s initial public offering could give the company a valuation between $50 billion and $55 billion in what may be the biggest offering...

September 1, 2023, 6:07 pm

Arm set to target ipo valuation of $50 billion to $55 billion, sources say

Arm Holdings Ltd is targeting a valuation between $50 billion to $55 billion for its much-awaited initi...

September 1, 2023, 5:57 pm

Arm looks to target ipo at $50-$55 billion valuation

Arm plans to start meeting with prospective investors as early as Tuesday...

September 1, 2023, 5:32 pm

50 large-cap high-yield stocks for september

Dogsofthedow.com recently published this list of 50 large-cap high-dividend stocks as of 8/31/23 per data from YCharts. The list ...

September 1, 2023, 3:41 pm

Roam outperforms eem by 7.4% ytd, limits losses

The Hartford Multifactor Emerging Markets ETF (ROAM) stands out for its outperformance over category peers such as EEM. ROAM is unique in that it is u...

September 1, 2023, 3:32 pm

Türkiye pursues policy shift with large rate hike but hefty inflation challenges remain

The Turkish central bank’s unexpectedly hawkish shift in policy helps rebuild credibility in inflation targ<...

September 1, 2023, 12:39 pm

Hudson technologies: target price revision after debt repayment

Hudson Technologies announces full repayment of outstanding term debt, resulting in over $10 million of annual savings on interest expenses. The compa...

September 1, 2023, 12:23 pm

Usdcad daily analysis – september 1, 2023

USD/CAD has recently broken below the rising price channel on the 4-hour chart, indicating that the previous upside movement from 1.3092 to 1.3639 has...

September 1, 2023, 9:50 am

Arvinas to participate in upcoming investor conferences

NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drug...

September 1, 2023, 7:00 am

Zeta global: still not enough growth to excite investors

Zeta Global provides AI tools for marketers to improve customer targeting and sales. The company's AI t...

September 1, 2023, 6:52 am


Search within

Pages Search Results: